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ABSTRACT
We examined quality of life (QoL) and other patient-reported outcome mea-
sures (PROMs) in 95 simultaneous pancreas and kidney transplant (SPKT)
recipients and 41 patients wait-listed for SPKT recruited to the UK Access to
Transplantation and Transplant Outcome Measures (ATTOM) programme.
Wait-listed patients transplanted within 12 months of recruitment (n = 22)
were followed 12 months post-transplant and compared with those still wait-
listed (n = 19) to examine pre- to post-transplant changes. Qualitative inter-
views with ten SPKT recipients 12 months post-transplant were analysed the-
matically. Cross-sectional analyses showed several better 12-month outcomes
for SPKT recipients compared with those still wait-listed, a trend to better
health utilities but no difference in diabetes-specific QoL or diabetes treatment
satisfaction. Pre- to post-transplant, SPKT recipients showed improved treat-
ment satisfaction, well-being, self-reported health, generic QoL and less nega-
tive impact on renal-specific QoL (ps < 0.05). Health utility values were better
overall in transplant recipients and neither these nor diabetes-specific QoL
changed significantly in either group. Pre-emptive transplant advantages seen
in 12-month cross-sectional analyses disappeared when controlling for baseline
values. Qualitative findings indicated diabetes complications, self-imposed
blood glucose monitoring and dietary restrictions continued to impact QoL
negatively post-transplant. Unrealistic expectations of SPKT caused some dis-
appointment. Measuring condition-specific PROMs over time will help in
demonstrating the benefits and limitations of SPKT.
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Introduction
Simultaneous pancreas–kidney transplantation (SPKT)
is generally considered the optimum treatment for
selected patients with insulin-dependent diabetes and
stage G5 chronic kidney disease (CKD) [1-4]. Pancreas
transplantation provides glycaemic control without the
need for exogenous insulin, can reduce the likelihood
of further damage from diabetic complications [3] and
extends life compared with kidney transplantation
alone [5,6]. As patient and graft survival rates
improve, the focus is shifting towards how SPKT can
improve other important nonclinical outcomes that
can help determine the ‘value’ of SPKT in health care
[7]. One of the first steps in addressing this question
is to ask patients themselves how their quality of life
(QoL) and other aspects of their lives are impacted by
their treatment, using patient-reported outcome mea-
sures (PROMs). Although it has been suggested that
QoL improves following transplantation [8], the mea-
sures most commonly used in SPKT research assess
health status not QoL [9]. For example, generic health
status measures such as the Short Form SF-36 [10]
and the EQ-5D [11,12] have shown that SPKT recipi-
ents report comparable outcomes to kidney-alone
transplant recipients [13-15]. A small number of stud-
ies have also compared SPKT recipients with those still
awaiting transplant and reported that SPKT recipients
have better scores on the SF-36 [14-16]. These studies,
however, are cross-sectional and do not include gen-
uine measures of QoL, so they cannot tell us how
QoL may be impacted by SPKT. For example, Poseg-
ger et al [16] measured the SF-36 in SPKT recipients
(less than one year, 1–3 years or> 3 years post-trans-
plant), and in those who were wait-listed for SPKT.
SPKT recipients reported better outcomes, but no pre-
transplant data were provided, so any differences may
have been present pretransplant and not caused by the
transplant.
Health status is only moderately associated with gen-
eric QoL [17] and is predicted by different variables
from those predicting QoL in people with type 2 dia-
betes [18]. Relying on health status measures in clinical
decision-making for transplantation risks overlooking
other aspects of life important to patients’ QoL [19,20].
The present study examines various PROMs, including
generic and condition-specific QoL along with health
status, in UK patients wait-listed for SPKT, and in those
who received SPKT. To provide a fuller and clearer pic-
ture of the outcomes of SPKT over time, analyses were
also conducted with a subsample of patients who pro-
vided PROMs data pretransplant as well as post-trans-
plant. This study also conducted qualitative interviews
to examine the experience of SPKT post-transplant, and
its impact on QoL.
Methods
Participants and procedure
This study was conducted as part of the UK Access to
Transplantation and Transplant Outcome Measures
(ATTOM) programme [21]. ATTOM aimed to examine
access to renal transplantation [22,23] and learn how to
optimize UK transplant outcomes. It consisted of five
work streams (i) examining factors that influence access
to transplantation; (ii) examining factors that affect sur-
vival on dialysis and after transplantation; (iii) examin-
ing differences in QoL and other PROMs in patients
undergoing dialysis or transplantation; (iv) conducting
health economics analysis of alternate approaches to
organ allocation; and (v) using the survival, health sta-
tus, QoL, treatment satisfaction and costs to determine
an optimal organ allocation policy for the UK. Specific
ATTOM methods are detailed elsewhere [21]. Following
ethical approval (East of England REC 11/EE/0120), and
obtaining informed consent, participants were recruited
from all UK renal and transplant units. The present
study was part of work stream 3 that investigated
detailed PROMs in patients undergoing various treat-
ments for CKD. Across all 72 renal units in the UK,
every patient < 75 years of age starting RRT from
November 2011 to March 2013 was invited to take
part in ATTOM. Of those patients recruited to
ATTOM, the first patient fluent in English recruited to
each centre each month who was either wait-listed for
SPKT or received SPKT was invited to take part in
work stream 3.
11 Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, UK
12 Health Psychology Research Ltd, Egham, UK
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To reflect the design of research previously conducted,
the first component of the study included cross-sectional
analyses that focused on participants recruited within
three months of receiving their SPKT (n = 117) and
patients wait-listed for SPKT (n = 41; see Fig. 1). Wait-
listed patients were matched to contemporaneous SPKT
recipients on the basis of age (within 5 years), time on
waiting list (+/ 100 days) and whether they were receiv-
ing dialysis before transplantation. Participants com-
pleted measures of health status and well-being at
recruitment. Generic QoL, renal- and diabetes-specific
QoL, and renal and diabetes current treatment satisfac-
tion measures were completed three months later via tele-
phone or post. Twelve months later, both patient groups
completed all questionnaires again, plus change versions
of the treatment satisfaction questionnaires which com-
pared satisfaction with current treatment (e.g. transplant)
and previous treatment (e.g. dialysis). During the follow-
up period, 22 of the 41 wait-listed patients received
SPKT. For this group, the initial questionnaires were
completed pretransplant when still wait-listed, whilst the
second set of questionnaires was completed 12 months
post-transplant (see Fig. 1). The second component
therefore involved analyses conducted with those partici-
pants with pre- and post-transplant data.
A third component of the detailed PROMs study used
semi-structured interviews (conducted by AG) to explore
in depth the effects of SPKT on QoL in ten SPKT recipi-
ents. Participants were invited to take part in an interview
if they had (i) received SPKT and (ii) completed the
Renal-Dependent QoL (RDQoL) measure [24]
12 months post-transplant. Participants were selected so
that they were representative of ATTOM SPKT recipients
for age, sex and ethnicity, and included participants with
a range of scores indicating high, low and average impact
of their renal condition on their QoL, to ensure the sam-
ple reflected the range of QoL outcomes of the overall
population. Participants were informed that the interview
would explore their questionnaire responses related to
their QoL and treatment satisfaction (see Appendix S1).
Interviews were audio-recorded and transcribed (Median
length = 56mins, range = 41-91).
Outcome measures
A summary of all outcome measures can be found in
Table S1. Condition-specific QoL was measured using the
Audit of Diabetes-Dependent Quality of Life (ADDQoL)
Questionnaire [25,26], modified for SPKT recipients (see
Appendix S2), and the Renal-Dependent Quality of Life
(RDQoL) Questionnaire [24]. These DQoL measures share
the same template. First, a single item asks participants to
rate their present QoL providing a generic QoL measure
(excellent +3 to extremely bad 3). Subsequent items
assess the impact of diabetes (ADDQoL) or the renal con-
dition (RDQoL) on QoL. Patients rate the impact of the
condition on various aspects of life (3 maximum negative
impact to + 1 positive impact), and the importance of each
aspect for their QoL (very important (3) to not at all
important (0)). Multiplying impact by importance ratings
gives a weighted impact (WI) score for each item. Some of
the items include preliminary questions to determine appli-
cability to the individual (e.g. employment). WI scores are
summed and divided by the number of applicable items to
give an average-weighted impact (AWI) score (maximum
negative impact 9 to most positive impact + 3).
Well-being was measured by the Well-Being Ques-
tionnaire (W-BQ12) [27,28]. Higher scores indicate bet-
ter well-being (range = 0-36). Health status was
measured by the EQ-5D-5L [13,14], which involves rat-
ing five dimensions of health on five levels. These data
were then converted into a population preference score
called a health utility value, using the new value set for
England [29,30] and methods encouraged by the
National Institute for health and Clinical Excellence
(NICE; https://www.nice.org.uk/). Higher health utility
values indicate better health status, whilst lower scores
indicate worse health status. They are measured on an
interval scale with zero reflecting states of health equiva-
lent to death and one reflecting perfect health. The EQ-
5D also asks participants to rate ‘your own health state
today’ on a visual analogue scale (EQ-VAS) from 100
(best health you can imagine) to 0 (worst health you
can imagine).
The Diabetes Treatment Satisfaction Questionnaire
status version (DTSQs) [31,32] assesses satisfaction with
diabetes treatment. Six items are summed to give a
treatment satisfaction score; higher scores indicate
greater satisfaction (range = 0-36). The change version
(DTSQc) [33,34] was developed to counteract ceiling
effects commonly found in satisfaction measurement
[33,34] and asks participants to compare their current
treatment with their previous treatment (range: +18
much more satisfied now, to  18 much less satisfied
now). Renal Treatment Satisfaction Questionnaire status
and change versions (RTSQs and RTSQc) [35], mod-
elled on the DTSQs and DTSQc, were also completed.
Analyses
Chi-squared tests and t tests were conducted to deter-
mine which, if any, demographic or medical factors
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needed controlling for in subsequent analyses. Cross-
sectional differences in outcomes in all participants who
received SPKT (n = 95) and those still remaining wait-
listed for SPKT (n = 19) at 12 months post-transplant/
postrecruitment were conducted using one-way analyses
of covariance (ANCOVA) controlling for sex, education
and previous treatment (dialysis versus predialysis).
Analyses examining pre- and post-transplant differences
over time were conducted using a series of 2 (group) x
2 (time) ANCOVAs with planned comparisons
Assessed for eligibility by 
research nurses in ATTOM
(n = 441)
Excluded (n = 305)
Not meeting inclusion criteria (n = 237)
Not approached or declined consent
(n = 68)
Completed questionnaires
(n = 13)
Received SPKT since 
recruitment
(n = 22)
Lost to follow-up (n = 6)
5 not contactable
1 known to have died
Wait-listed for SPKT (n = 41)
Completed questionnaires
(n = 41)
Completed questionnaires
(n = 64)
Lost to follow-up (n = 31)
26 not contactable
1 too ill
4 known to have died
SPKT recipients (n = 95)
Completed questionnaires
(n = 95)
Interviewed 12-15 m post-
transplant (n = 10)
Excluded (n = 76)
♦ Not meeting inclusion 
criteria (n = 65)
♦ Declined to participate 
(n = 2)
♦ Not contactable (n = 4)
♦ Not contacted (n = 5)
Recruitment
Interviews
12 m follow-up
Recruited (n = 136)
Enrollment
Wait-listed group 
received SPKT since 
recruitment (n = 22)
Completed 
questionnaires (n = 14)
Lost to follow-up (n = 8)
7 not contactable
1 known to have died
Figure 1 CONSORT diagram showing number of participants and timing of questionnaire completion
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(controlling for sex and pretransplant treatment). These
analyses were undertaken with the 41 patients recruited
when wait-listed, and who were either still wait-listed
(n = 19) after 12 months, or subsequently transplanted
(n = 22). One-way ANCOVAs controlling for sex, pre-
transplant treatment and initial treatment satisfaction
status scores were also conducted with these 41 patients,
to examine differences between groups in treatment sat-
isfaction change measures comparing satisfaction with
treatment at 12 months post-transplant compared with
previous renal or diabetes treatment (dialysis or insulin
treatment regimen).
Thematic analyses of qualitative data, based on a
pragmatic approach, were conducted according to
established guidelines [36]. Initial coding (AG) estab-
lished themes derived from the data. These enabled
development of a coding framework (AG, MC, CB),
which showed significant inter-rater agreement during
subsequent coding (AG and JB). The coding, completed
in MS Word, was entered into NVivo10 software (QSR
International, USA) for qualitative analysis.
Results
The demographics of the 117 patients who underwent
SPKT during ATTOM and the 19 patients remaining
wait-listed at 12 months are shown in Table 1. Twenty-
five SPKT recipients (21%) were transplanted before
starting dialysis (Table 1), whilst five (26%) wait-listed
patients were not on dialysis when first listed. At
12 months, 26 (19.1%) participants did not return
completed measures, 14 (10.3%) could not be con-
tacted, 1 (0.1%) person was too ill, and 4 people (2.9%)
were known to have died. There were no significant dif-
ferences between responders and nonresponders in sex,
ethnicity, employment status, civil status, education,
renal replacement therapy (RRT), type of donor (dona-
tion after brainstem death (DBD) or donation after cir-
culatory death (DCD)), recruitment PROMs or utility
measures.
Differences in outcomes
A significantly higher proportion of women were wait-
listed for SPKT (68.4%) than received SPKT (42.7%)
compared with men (31.6% wait-listed patients were
men, 57.3% received SPKT; v2 = 4.3, df = 1, P = 0.04).
Those remaining wait-listed at 12 months were more
likely to have the minimum standard schooling than
those receiving a transplant (v2 = 4.6, df = 1, P = 0.03).
There was no difference in education level in those
patients who were wait-listed at recruitment and who
either went on to have a transplant, or remained wait-
listed (v2 = 6.34, df =3, P = 0.09).
Among recipients of SPKT, outcomes at 12 months
did not differ by donor type (DBD or DCD; ps> 0.05),
or previous RRT (ps> 0.05). However, those who
received dialysis prior to transplantation reported
greater improvements over time in generic QoL
(M=0.3, SD = 1.5 to M = 1.5, SD = 0.8; P = 0.01),
renal treatment satisfaction (M = 51.8, SD = 11.9 to
M = 72.8, SD = 5.4; P < 0.001) and diabetes treatment
satisfaction (M = 26.9, SD = 8.1 to M = 34.1, SD = 4.1;
P = 0.02) than those pre-emptively transplanted. Subse-
quent analyses controlled for sex and previous RRT,
whilst level of education was also controlled for in
cross-sectional analyses.
Cross-sectional analyses compared all patients who
received a transplant to those still wait-listed at
12 months, controlling for differences in sex, previous
RRT and education (Table 2). SPKT recipients reported
better generic QoL (P = 0.01), total well-being
(P < 0.001), health status (EQ-VAS, ps < 0.001), renal
treatment satisfaction (P = 0.03) and less negative
impact of the renal condition on QoL compared with
those wait-listed (P = 0.01). There were no between-
group differences in impact of diabetes on QoL
(P = 0.9) or diabetes treatment satisfaction (P = 0.8),
or health utility values (P = 0.09) at 12 months. These
analyses do not consider pretransplant data and there-
fore do not take account of baseline differences or
changes over time.
For the subsample of 41 patients recruited whilst
wait-listed, we examined differences between those who
were still wait-listed at one year (n = 19) and those
who subsequently had a transplant (n = 22), controlling
for sex and previous RRT. There were no significant dif-
ferences between groups at recruitment, although there
was a trend for those patients who went on to receive
SPKT to have better health utility values (P = 0.08). As
can be seen in Figs 2 and 3, significant interaction
effects between groups and over time were found for
generic QoL, renal-specific QoL (RDQoL AWI scores),
well-being, EQ-VAS self-reported health and renal treat-
ment satisfaction (ps < 0.05). For these outcomes, those
patients who remained wait-listed reported no change
in scores over time. In contrast, those who received
SPKT reported improved generic QoL (P = 0.01), well-
being (P = 0.05), EQ-VAS self-reported health
(P = 0.01), renal treatment satisfaction (RTSQs;
P < 0.001) and less negative impact of their renal con-
dition on QoL (RDQoL AWI scores; P = 0.04). These
1234 Transplant International 2020; 33: 1230–1243
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outcomes were significantly better for SPKT recipients
at 12 months. Diabetes-specific QoL (ADDQoL AWI
scores) remained stable over time for both groups
(P = 0.2). At 12 months, SPKT recipients had signifi-
cantly better health utility values than those still wait-
listed (P = 0.01), but neither group showed significant
changes in values over time (P = 0.6). However, 20.5%
of SPKT recipients had worse health utility scores post-
transplant, but many fewer reported worse QoL scores
post-transplant (6.3% reporting worse generic QoL and
Table 1. Summary of demographic characteristics
Transplant (n = 117) Wait-listed (n = 19) Difference between groups
Variable Mean (SD) Mean (SD) P
Age (years) 42.3 (8.4) 42.3 (6.8) 0.99
Variable n (%) n (%) P
Sex: Female 50 (42.7) 13 (68.4) 0.04
Previous experience of SPKT failure 10 (8.5) 2 (10.5) 0.83
Primary renal diagnosis 0.88
Diabetes (type 1) 108 (92.6) 18 (94.7)
Diabetes (type 2) 1 (0.8) 1 (5.3)
Renal vascular disease (hypertension) 1 (0.8) 0 (0.0)
Glomerulonephritis 1 (0.8) 0 (0.0)
IgA nephropathy 1 (0.8) 0 (0.0)
Unspecified diagnosis 1 (0.8) 0 (0.0)
Missing 4 (3.4) 0 (0.0)
Pretransplant treatment 0.75
Predialysis 25 (21.4) 5 (26.3)
Peritoneal dialysis (PD) 34 (29.1) 3 (15.8)
Haemodialysis (HD) 50 (42.7) 11 (57.9)
Failing transplant 2 (1.7) 0 (0.0)
Missing 6 (5.1) 0 (0.0)
Comorbid conditions
Heart disease 10 (8.8) 2 (10.5) 0.81
Heart failure 1 (0.9) 1 (5.3) 0.15
Cardiovascular disease 10 (8.8) 4 (21.1) 0.25
Pulmonary disease 13 (11.5) 2 (10.5) 0.90
Respiratory disease 5 (4.4) 0 (0.0) 0.35
Malignancy 2 (1.8) 0 (0.0) 0.56
Mental illness 15 (13.3) 2 (10.5) 0.74
Marital status 0.77
Single 38 (32.5) 5 (26.3)
Living with partner 10 (8.5) 3 (15.8)
Married 47 (40.2) 8 (42.1)
Divorced/Separated 12 (10.2) 2 (10.5)
Widowed 3 (2.6) 0 (0.0)
Missing 7 (6.0) 1 (5.3)
Ethnicity 0.49
White 97 (82.9) 15 (78.9)
Black 6 (5.1) 2 (10.5)
Asian 4 (3.5) 0 (0.0)
Mixed 2 (1.7) 1 (5.3)
Missing 8 (6.8) 1 (5.3)
Education 0.15
Minimum standard schooling 13 (11.1) 5 (26.3) 0.033
Completed secondary education with qualifications 36 (30.8) 4 (21.1) 0.592
Higher education 14 (11.9) 4 (21.1) 0.597
Other qualifications (e.g. NVQ1-5) 48 (41.1) 5 (26.3) 0.431
Missing 6 (5.1) 1 (5.2)
Higher education qualifications include bachelor’s degree, higher degree. Secondary education qualifications include A-level
and/or GCSE.
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4.9% more negative impact on their renal-specific
QoL). Diabetes treatment satisfaction (DTSQs)
increased over time (P < 0.01), with no between-group
differences (P = 0.9; Fig. 2).
Controlling for sex, previous RRT and pretrans-
plant RTSQs scores, there was greater improvement
in satisfaction with renal treatment at 12 months
compared with baseline treatment (RTSQc) for those
who were recruited whilst on the waiting list who
subsequently received an SPKT (M = 31.6, SE = 3.9)
than for those who remained wait-listed (M = 11.9,
SE = 4.8; F(1, 17)= 9.6, P = 0.007; see Fig. 3). The
DTSQc also showed greater improvements in satis-
faction with diabetes treatment in SPKT recipients
(M = 13.9, SE = 2.1) compared with those wait-listed
(M = 5.8, SE = 2.9; F(1, 12)= 5.1, P = 0.04). This is
in contrast to the DTSQs, where 75.7% recipients
scored at or near ceiling prior to transplantation,
and 83.6% at 12 months post-transplant, showing
that the majority of participants could not improve
their status scores.
Qualitative interviews
Participants discussed the impact of their renal condi-
tion and diabetes on their QoL, the ways in which
their transplant had minimized the negative impact of
their conditions on their QoL, and how their diabetes
continued to impact negatively on their QoL post-
transplant. Illustrative examples of these themes can
be seen in Table 3. Before transplantation, recipients
reported that work, leisure activities, physical ability,
diet and relationships were all negatively impacted by
their renal condition. Diabetes led to eyesight prob-
lems, neuropathy, mobility problems and undesirable
dietary restrictions, and had a negative impact on
social activities and work. Post-transplant, participants
reported improved physical ability, greater indepen-
dence and dietary freedom. Despite having a function-
ing pancreas transplant, recipients still reported that
their diabetes negatively impacted their QoL. Compli-
cations such as retinopathy were still affecting the
ability to work and drive. Having expectations of
transplant that were not realized (e.g. size of scar) led
to distress and negatively impacted QoL post-trans-
plant. For example, one woman was shocked by the
size of her scar post-transplant, which led to feelings
of anxiety about being considered ‘damaged goods’.
This made her feel less able to disclose her condition
to others, which she perceived as an obstacle in find-
ing a partner. Many participants were anxious about
how long their transplant would remain functional.
Six of the ten SPKT recipients interviewed more than
one year post-transplant reported still restricting their
diet and/or checking their blood sugars frequently, as
a result of this anxiety.
Table 2. Summary of means (M) and standard errors (SE) of outcomes (controlling for sex, education and pretransplant
treatment) across groups at 12 months post-transplant/postrecruitment
a. Group at 12 months
Transplant
(n = 78)
Wait-listed
(n = 12)
F df PPatient outcomes M SE M SE
Generic QoL (RDQoL) 1.23 0.14 0.04 0.37 8.85 83 0.004
Renal-specific QoL (RDQoL AWI) 2.62 0.21 4.43 0.59 7.95 81 0.006
Total well-being (W-BQ12) 24.59 0.84 15.92 2.34 11.82 81 <0.001
Health status (EQ-VAS ratings) 76.22 2.20 45.92 5.74 23.85 82 <0.001
Health utility values (EQ-5D-5L) 0.78 0.02 0.64 0.07 3.04 81 0.085
Current renal treatment satisfaction (RTSQs) 69.82 0.97 63.63 2.54 5.11 82 0.027
Change in renal treatment satisfaction (RTSQc) 31.29 1.16 12.77 3.17 29.69 81 <0.001
Diabetes-specific QoL (ADDQoL AWI) 3.58 0.25 3.51 0.64 0.01 80 0.923
Current diabetes treatment satisfaction (DTSQs) 32.66 0.74 32.26 1.90 0.04 79 0.849
Change in diabetes treatment satisfaction (DTSQc) 14.35 0.84 4.40 2.45 14.59 74 <0.001
QoL = quality of life; RDQoL = Renal-Dependent Quality of Life Questionnaire; AWI = average-weighted impact score; EQ-
VAS = visual analogue scale; RTSQs = Renal Treatment Satisfaction Questionnaire – status version; RTSQc = Renal Treatment
Satisfaction Questionnaire – change version; ADDQoL = Audit of Diabetes-Dependent Quality of Life Questionnaire;
DTSQs = Diabetes Treatment Satisfaction Questionnaire – status version; DTSQc = Diabetes Treatment Satisfaction Question-
naire – change version.
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Discussion
This study shows some positive benefits of SPKT on
patient-reported outcomes. The negative impact of par-
ticipants’ renal conditions on QoL reduced following
transplantation, but surprisingly, the negative impact of
diabetes on QoL showed no such improvement. This
finding can be explained in part by the qualitative find-
ings, which show that although participants reported
positive changes, their QoL continued to be impaired by
long-standing diabetes-related complications. These com-
plications limited the positive impact of the transplant on
their QoL. Previous research has shown that although
SPKT recipients reported better physical health outcomes
[1-6], they did not report better mental health when
compared with kidney-only recipients [14]. Although not
actively encouraged to continue to check their blood
Figure 2 Differences in outcomes (controlling for sex and previous renal replacement therapy) at pretransplant/recruitment and at 12m post-
transplant/12m postrecruitment in those who remained wait-listed for an SPKT (n = 19), and those who received an SPK transplant after
recruitment (n = 22). Note: *indicates main effects of differences between groups post-transplant: *P < 0.05; **P < 0.01; ***P < 0.001. EQ-
5D VAS = visual analogue scale rating; RDQoL = Renal-Dependent Quality of Life Questionnaire; AWI score = average-weighted impact score;
ADDQoL = Audit of Diabetes-Dependent Quality of Life Questionnaire. RTSQs = Renal Treatment Satisfaction Questionnaire (status version);
DTSQs = Diabetes Treatment Satisfaction Questionnaire (status version)
Figure 3 Bar graphs showing differences in treatment satisfaction change scores (controlling for sex, previous renal replacement therapy and
baseline treatment satisfaction scores) in those who remained wait-listed for an SPKT (n = 19), and those who received an SPKT after recruit-
ment (n = 22). Note: RTSQc: Renal Treatment Satisfaction Questionnaire (change version); DTSQc Diabetes Treatment Satisfaction Question-
naire (change version). Positive scores indicate improved satisfaction with the current treatment compared with the previous treatment.
Negative scores indicate a deterioration in satisfaction with the current treatment compared with the previous treatment. A score of zero indi-
cates no change in satisfaction. Main effects between groups for RTSQc and DTSQc are significant (ps < 0.05)
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glucose levels by medical staff, many participants reported
anxiety surrounding graft loss. Anxiety led many to adopt
self-imposed dietary restrictions. Frequent blood glucose
testing was also commonly carried out more than one year
post-transplant. Participants believed these measures sup-
ported their graft survival. This anxiety and uncertainty
about the future has been shown in previous research
[37]. For example, Kwiatkowski et al.[38] reported that in
19 SPKT recipients, all reported greater life satisfaction,
but after an average of four years post-transplant, only
four had returned to work, 12 reported fear of graft loss,
14 checked their glucose levels daily, and 8 reported feel-
ing sad or depressed. Dietary freedom is the aspect of life
that is usually most damaged by diabetes, and is consid-
ered by patients to be very important for QoL [25,26,39],
so continuing to restrict dietary freedom, when not
deemed medically necessary, may continue to damage
QoL post-transplant. SPKT recipients may require guid-
ance and support about how to protect and monitor their
SPKT and maintain a healthy diet, whilst also protecting
their QoL. To improve diabetes-specific QoL, SPKT recip-
ients could be encouraged to challenge their behaviour
and beliefs by checking and recording one fasting and one
postprandial blood glucose per day for two weeks of con-
tinued restricted diet followed by two weeks of dietary
freedom and discussing the results with their doctor, dia-
betes specialist nurse or health psychologist. Such a beha-
vioural change intervention has the potential to improve
QoL but needs pilot testing with monitoring of anxiety as
well as QoL. More generally, although some patients felt
well-prepared for the realities of the experience of SPKT
and its effects on their lives, others did not. The greater
the disparity between expectations and reality (e.g. the size
of post-transplant scar), the more distress experienced by
participants. More precise information, prior to listing for
SPKT, is needed, to ensure that the decision to be wait
listed for SPKT is fully informed and avoid the shock and
regret that may otherwise follow overly optimistic expec-
tations.
Satisfaction with diabetes treatment, measured by the
DTSQ status measure, did not improve following trans-
plantation, but most participants reported very high/
maximum levels of satisfaction pretransplant. These
ceiling effects were overcome by the DTSQ change ver-
sion, which allowed participants to report greater satis-
faction at follow-up even when very satisfied at baseline.
The DTSQc showed significantly greater improvements
in satisfaction in those transplanted compared with
those still wait-listed. This highlights the importance of
using both status and change versions of treatment sat-
isfaction questionnaires in such research.
SPKT recipients reported greater well-being and gen-
eric QoL at 12 months compared with those wait-listed
and showed improvements in scores pre- to post-trans-
plantation. Transplant recipients reported better self-
rated health status pre- to post-transplant in the form
of EQ-VAS ratings. Transplant recipients tended to have
better health utility values pretransplant than those who
remained wait-listed, and this trend became significant
at 12 months, primarily because of baseline differences
as there were no significant changes over time.
Although SPKT can help improve long-term survival
and prevent worsening of diabetes complications, it is
not an immediately life-saving operation, so it is partic-
ularly important to have a complete picture of patient-
reported outcomes when assessing cost-effectiveness
including all pros and cons. Focusing only on the health
utility measure would lead to the benefits of SPKT
being underestimated, as they do not reflect the
improvements seen with other PROMs. Going forward,
it will be valuable to monitor patient-reported outcomes
routinely in all wait-listed patients, to determine
changes over time and with a longer follow-up post-
transplantation, and such studies are underway.
Those on dialysis prior to transplantation reported
greater improvements in generic QoL and satisfaction
with both diabetes and renal treatments when compared
with those pre-emptively transplanted, although no dif-
ferences were apparent in 12-month cross-sectional
analyses. The pre-emptive group made fewer gains over
time, whilst those who were receiving dialysis reported
greater improvements until they were comparable to
those pre-emptively transplanted. Pre-emptive trans-
plantation is considered by many to be more beneficial
for patients, but these findings suggest once pretrans-
plant scores are controlled, there are no group differ-
ences 12 months post-transplant.
This is the first study to measure renal-specific and
diabetes-specific QoL in SPKT and is the first to exam-
ine quantitative changes in PROMs pre- to post-trans-
plant, together with qualitative data to understand the
PROMs findings. However, this study had some limita-
tions. The sample for whom pretransplant data were
available was relatively small, with attrition over time.
Despite this, most previous research has been cross-sec-
tional, so although the small sample size may limit the
generalizability of our longitudinal sample, the overlap-
ping much larger cross-sectional sample replicates some
of the findings (e.g. in QoL and well-being) but not
others where it can be seen that pretransplant measures
are important for understanding 12-month outcomes
(e.g. ceiling effects at baseline in treatment satisfaction:
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Table 3. Summary of qualitative themes with illustrative quotations
Theme Illustrative quotations
Impact of renal
condition before
transplant
Physical ability:
• I hadn’t realised how tired I was getting. Woman, pre-emptive SPKT.
• I was constantly very tired; looked very yellow, gaunt, and just really running out of energy. And I
kept getting gout and cellulitis. Man, pre-emptive SPKT.
Leisure activities:
• I had stopped going out. . . at night time I still had to plug into the machine and everybody said
are you coming out and I’d be like no I have to plug in by 10 o’clock. Woman, SPKT following CAPD.
• I had to make an effort of not going anywhere very far. I couldn’t go abroad because I had to be
at a maximum four hours away from the hospital in case (the call for a transplant) came through.
Man, pre-emptive SPKT.
Work:
I sort of gave up work as well cos I just you know I couldn’t cope. . .I gave up work because I knew that
my health was deteriorating and I thought it was best for myself and my employer that I gave up work
to look after my health. Woman, SPKT following HD.
Diet:
• When I was on dialysis (before the transplant), I was on a low potassium diet which was very,
very strict and I could only drink 500mls a day. Man, SPKT following HD.
Relationships:
• I mean obviously I was at home all the time but I wasn’t physically able to do a great deal so it
still meant that I was putting a lot of pressure on my partner. She was going to work and then she
was coming home and cooking and things like that. Man, SPKT following CAPD.
Impact of diabetes
before transplant
Neuropathy or mobility:
• I had trouble with my eyes, then my nerve damage. Man, pre-emptive SPKT.
• As a by-product, or maybe partly a by-product, I got what’s called Charcot foot. Man,
pre-emptive SPKT.
• I’m limited to the use of that hand. Woman, SPKT following HD.
Eyesight:
• Looking at a computer screen, unless I’ve got the magnifier up, I can’t see normal print. I think
for instance like if I wanted to like sew something, I couldn’t thread a needle and that would be
because of my eyesight (from the diabetes). Woman, SPKT following HD.
Lifestyle:
• The main thing, the other thing is about the diabetes, that was SO restrictive, it was just ah well I
never actually, I mean I knew it was bad, it was a full-time thing. You couldn’t get rid of it, and you
had to; I had to watch you know it was all through the night I was doing blood tests probably um every
hour usually during the night. Through the day wasn’t that bad but you had to just watch; your
blood sugars were all over the place you know they’d be high and then you just couldn’t guess,
well you couldn’t work out what was happening. That was the main thing. Man, SPKT following HD.
Work:
• I was getting fed up of being a diabetic because I was missing out on a lot of things in work.
And also, I was losing my job because of being a diabetic. I used to be a driver driving a
seven-and-a-half-ton truck but I lost my job because the government brought in a rule
that you can’t drive an HGV when you’re diabetic so I lost my job. Man, pre-emptive SPKT.
Social activities/self-confidence:
• I think the diabetes initially it used to put a strain on social activities again to be honest with you.
I constantly needed the loo. . .It was things like travelling were a bit of an issue, with driving. Man,
SPKT following CAPD.
Minimizing impact
post-transplant
• I mean it has cured the diabetes. Man, SPKT following HD.
• I’m grateful for both organs. It’s prolonged my life, it’s stopped me from going to hospital 3 times
a week for dialysis, it’s given me lots of energy, I’ve got back my, you know some of my independence.
Woman, SPKT following HD.
• Well as far as I’m concerned, I’m just, my life is as I would be as I was before I had to have
dialysis. Man, SPKT following HD.
• I’m not on insulin anymore; I’m not insulin dependent anymore. And I can eat within reason. . .
everything that is put in front of me, and that’s including chocolate! Man, pre-emptive SPKT.
• It’s much better; I’m much freer with what I can eat. Man, pre-emptive SPKT.
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health utility values that were better at baseline in those
who went on to receive SPKT versus those remaining
on the waiting list). With the longitudinal data, we can
also see that PROMs were better at baseline in those
who were pre-emptively transplanted compared with
those transplanted following a period on dialysis and it
was the latter who showed most benefit from SPKT.
There was a higher proportion of women than men still
Table 3. Continued.
Theme Illustrative quotations
Ongoing negative
impact of diabetes
post-transplant
Ongoing complications:
• It’s the damage done beforehand, it’s not repairable, and it’s not going to get any better.
Woman, SPKT following HD.
• I think the health situation is much better, . . . It’s just the legacy of personal, financial, career
things around it that have possibly not turned out as well. . .it’s not over. I just feel that with other
conditions you get fixed and then it is fixed. That’s the difference. Woman, SPKT following CAPD.
• I just sometimes I still feel like I have no future. . . for example if I’m going to get a partner now,
I don’t know if some people from certain cultures will be like ‘oh no don’t touch her because her
life expectancy or health isn’t too good, how’s she gonna have kids?’ I still feel. . . that kind of feeling
of damaged goods. Woman, SPKT following CAPD.
• The (driving) licence has got to be renewed every three years; I’m on a three-yearly licence.
It’s due for renewal this year so this is where the question (of whether I still have diabetes is
going to come up. Man, pre-emptive SPKT.
• If you’re diabetic if you apply for jobs, I know because under the Disability Act they’re supposed
to ignore it. But they don’t and I’ve had this time and time again from other people who I know
who are diabetic, who know damn well it’s not ignored. And in that respect, I think it affected
my career and what I could do in the past. A lot of people are very nervous about taking someone
on with diabetes and um, I think they still would be you know even with having the pancreas
transplant. I think they still would be. Man, pre-emptive SPKT.
• Even though I’m not insulin dependent anymore I’m still classed as a diabetic. Man, pre-emptive
SPKT.
• In my head I was always thinking. . . when that call comes through that they’ve got your kidney,
everything will be fixed and everything will go back to normal. I’ll get my health back, I’ll be able
to do activities, I’ll be able to go out, I wouldn’t have a tube in my stomach. But then the same
anxieties from the tube in my stomach and from people seeing the tube has now been
transferred to people seeing my scar, which is quite a large scar. Woman, SPKT following CAPD.
• Just because I now no longer have to take insulin and I am at the moment no longer a
diabetic, doesn’t mean that I won’t still. . . there is still a possibility that any of these complications
could still happen to me, any time you know even late in life because I was diabetic for 30 years.
Man, SPKT following HD.
Continued impact on diet:
• If I get a cold drink from a shop or something like that, I will still automatically go for the diet
option. Man, SPKT following CAPD.
• I couldn’t bring myself to eat anything (sweet) after so long. Man, pre-emptive SPKT.
• I’d been on a carbohydrate counting diet since I was 8 and rather weirdly, I’m still on the same
thing, from choice. It’s not that I stand there religiously with a pair of scales, but all the time
I’m eating I’m still very, very aware that potato is about 40 grams. I just can’t get it out of
my system. Man, pre-emptive SPKT.
Blood glucose monitoring:
• (I check my blood glucose) daily at the moment. Well once a day, maybe once a day. Once a day
just after I’ve had my breakfast and just before I go out that’s when I check it and I don’t bother
checking it any other time. I still do, just, just to be safe and to be sensible about it and just
put my mind at rest. Man, SPKT following HD.
• I’ve still got to be careful with what I’m eating, I’ve got to watch what I eat. I monitor myself
every few days . . .I do it every two days and I do it twice every two days. Man, pre-emptive SPKT.
• I test my blood once in a blue moon, once a week now just every now and again. That’s for
my own benefit rather than anything else. The hospital told me I don’t need to but they do
1240 Transplant International 2020; 33: 1230–1243
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Gibbons et al.
wait-listed one year postrecruitment compared with
those transplanted. UK-wide figures for 2011-2014
showed similar rates for men and women on the
nationwide waiting list (52% men), and those trans-
planted (55% men) [40-42], despite the fact that the
UK kidney offering policies do not discriminate on sex
or educational background. It is not clear why we found
a bias in SPKT favouring men during the period of our
study (2011-2014). The analysis controlled for these fac-
tors when analysing the PROMs data to minimize the
effects of any bias. Those who took part at 12 months
post-transplant all had functioning grafts, so the find-
ings do not reflect the QoL and PROMs of those few
patients whose transplants failed. Patients who experi-
ence failed transplants are likely to have more negative
outcomes in terms of PROMs and would need to be
considered in evaluating the overall impact of SPKT.
The comparative wait-listed group was small, but there
were no baseline differences between 12-month respon-
ders and nonresponders, suggesting that our responders
were sufficiently representative of the original larger
sample. Twelve-month follow-up may be insufficient for
the full benefits of SPKT to emerge and current work
includes a longer-term follow-up of these ATTOM
patients. As this study focused on patient-reported out-
comes, we do not have detailed clinical outcome data
such as the number of post-transplant complications
experienced by patients, but any effects of such compli-
cations on QoL and treatment satisfaction will have
been captured by the PROMs used.
Measuring PROMs pretransplant increased our under-
standing of changes over time suggesting transplantation
improved well-being, QoL, treatment satisfaction and
patient-reported health (but not health utility values).
Measuring condition-specific PROMs over time demon-
strates the benefits and limitations of SPKT and identifies
opportunities for further QoL improvements through,
for example, guidance and support about how best to
protect and monitor their SPKT, whilst avoiding the
quality of life damaging and medically unnecessary diet-
ary restrictions and blood glucose monitoring.
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Theme Illustrative quotations
ask me every time I go if I have done and what it was! I keep doing it I think more for their
sake than mine now but I do it every now and again. Man, SPKT following HD.
Expectations of
transplant
• In my head I was always thinking. . .everything will be fixed and everything will go back to normal,
but it did shock me because I didn’t think (the transplant scar) would be from breast bone down to
the groin. I never thought it would be that big. . . when I saw the huge staples, I just felt they didn’t
care enough to even use some neat stitches, they used staples. Woman, SPKT following CAPD.
• When (healthcare staff) are giving out all the information before you have the transplant, the
last thing that they want to do is to put you off by saying well you know, you could be really ill
afterwards. . . but I don’t actually think that you ever really prepare yourself for that because you
hope of course that that’s not going to be you, and you don’t expect it to be you either, even
though you know that it could be, you don’t think it will be. Woman, pre-emptive SPKT.
• (The professor) who’s the main transplant man, he said . . . once you’ve had (the transplant)
done, you’ll feel so appalling, you’ll think why on earth have I done that? So, they are, actually
they’re brutally honest and actually I think they prepare you extremely well. Man, pre-emptive SPKT.
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